Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Core Gross Profit: $45,515M in FY2025, up 8.7% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
45,515
Period ended Dec 31, 2025
Change on a year earlier
+8.7%
41,872 in FY2024
History
8 years
Since FY2017
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Gross profit | 42 975 | 2 805 | 59 | -324 | 45 515 | 41 872”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Core Gross Profit ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 45,515 | +8.7% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 41,872 | – | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2022 | Dec 31, 2022 | 37 | -44.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2021 | Dec 31, 2021 | 67 | -38.5% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 109 | -90.3% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2019 | Dec 31, 2019 | 1,123 | +1,504.3% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 70 | -56.8% | Novartis Form 6-K (0001370368-19-000006) ↗ |
| FY2017 | Dec 31, 2017 | 162 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Cite this data
StockData. (2026). Novartis Core Gross Profit ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/core-gross-profit
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.